BA
INDV icon

Bridgewater Associates’s Indivior Pharmaceuticals INDV Stock Holding History

Bridgewater Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Buy
68,181
+31,040
+84% +$1.13M 0.01% 619
2026
Q1 		$1.13M Buy
+37,141
New +$1.23M 0.01% 771

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgewater Associates's INDV Position: Q2 2026 in Review

Bridgewater Associates increased its Indivior Pharmaceuticals (INDV) stake by 84% in Q2 2026, buying an estimated $1.13M and bringing the position to 68,181 shares worth $2.8M. The position accounts for 0.01% of the portfolio, ranked #619.

Bridgewater Associates first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Bridgewater Associates held 68,181 shares of Indivior Pharmaceuticals worth $2.8M as of Q2 2026.
  • Bridgewater Associates bought 31,040 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.13M.
  • Indivior Pharmaceuticals made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #619 holding.
  • Bridgewater Associates first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.